Opinion|Videos|January 8, 2025
International Lipid Expert Panel Recommendations and RACING Trial
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how the International Lipid Expert Panel advocates for combination therapy as initial treatment in patients with elevated LDL-C and very high cardiovascular risk rather than sequential monotherapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The International Lipid Expert Panel recommends combining therapies as a first-line treatment approach for patients who have elevated LDL-C and a very high risk for a cardiovascular event.
Advertisement
Related to this article
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.
Five CHEST 2026 interviews cover nalbuphine ER for IPF cough, tozorakimab in COPD, depemokimab remission, AD109 in OSA, and robotic bronchoscopy.
Psoriasis advocates Nitika Chopra and Ayesha Patrick address common misconceptions, how patients can speak up, and simple tips for clinicians.
The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Nalbuphine ER Rapidly Eases IPF Cough Burden, With Phil Molyneaux, MD, PhD
2
Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis
3
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
4
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
5